{
  "id": 15313406,
  "title": "Clover Health CEO Andrew Toy sells $1.3m in shares",
  "url": "https://urgent.news/2026/10/18/clover-health-ceo-andrew-toy-sells-1-3m-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-18T00:16:05.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/clover-health-ceo-andrew-toy-sells-13m-in-shares-93CH-4955703"
  },
  "original_language": "en",
  "account": "On October 1, 2026, Clover Health CEO Andrew Toy sold 318,806 shares of the company’s Class A Common Stock, as reported in a recent SEC Form 4 filing. The transaction was worth approximately $1,335,797 and was executed to satisfy tax withholding obligations related to the vesting of 6.25% of restricted stock units granted to Toy on January 1, 2023. The shares were sold at an average price of $4.19 per share, with individual transaction prices ranging from $4.18 to $4.21. These sales were not discretionary but were required by Clover Health’s equity incentive plans. Following the transactions, Toy beneficially owns 9,140,510 shares of CLOV’s stock. CLOV’s stock has seen strong performance, with a 65% return over the past year and a 105% gain over the last six months, though it is currently deemed slightly overvalued according to InvestingPro data. Despite these recent sales, Clover Health reported strong second-quarter earnings for 2026, surpassing Wall Street’s expectations with adjusted earnings of 5 cents per share on revenue of $743.2 million. The company has also raised its full-year outlook. This development highlights Clover Health's continued growth in a competitive healthcare market, garnering significant investor and analyst interest.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Maze Therapeutics CEO Jason Coloma sells $932,259 in Maze shares",
        "url": "https://urgent.news/2026/10/17/maze-therapeutics-ceo-jason-coloma-sells-932-259-in-maze-shares",
        "published": "2026-10-17T23:46:17.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}